Report

PSA Pharma: Eisai’s (4523 JT) Lecanemab Results Presentation

Eisai (4523 JT) presented the results of its Clarity AD trials for lecanemab to an Alzheimer’s Disease conference in San Francisco on 29 Nov. Unsurprisingly, since it met its primary and secondary endpoints, the drug would appear to work. The only problem is the issue of “Why doesn’t it work better”? And the answer to that is “Actually, it might, but the trial ended too soon”.
Underlying
Eisai Co. Ltd.

Eisai is mainly engaged in the manufacture and sale of pharmaceutical products. Co.'s principal prescription drugs include anticancer agents, anti-Alzheimer's agent, anti-TNF monoclonal antibodies, antiepileptic agents, proton pump inhibitors, neuropathic pain relievers, and other prescription drugs under the name of "Halaven," "Lenvima," "Fycompa," "BELVIQ," "Pariet/AcipHex," "Aricept," and "Humira." Co.'s principal over-the-counter products include Vitamin B2 preparations "Chocola BB," gastrointestinal drugs, anti-allergic drugs, and dermatological preparations. Co. operates its operations in Japan, the Americas, Europe, China and Asia.

Provider
Pelham Smithers Associates Ltd
Pelham Smithers Associates Ltd

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries. 

The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012. 

Analysts
Pelham Smithers

Other Reports on these Companies
Other Reports from Pelham Smithers Associates Ltd

ResearchPool Subscriptions

Get the most out of your insights

Get in touch